What Does Wall Street Think About Vaxcyte (PCVX)?

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best strong buy stocks to invest in according to Wall Street. Goldman Sachs initiated coverage of Vaxcyte, Inc. (NASDAQ:PCVX) on September 12 with a Neutral rating and a $38 price target.

Is Chevron Corporation (CVX) the Low Volatility Stock to Buy According to Billionaire Ken Fisher?

However, Mizuho Securities analyst Salim Syed maintained a Buy rating on Vaxcyte, Inc. (NASDAQ:PCVX) on August 16, setting a price target of $163.00.

Similarly, Seamus Fernandez from Guggenheim also reiterated a Buy rating on Vaxcyte, Inc. (NASDAQ:PCVX) on August 7, setting a $116 price target.

Currently, the analyst consensus on Vaxcyte is a Strong Buy, and the stock’s median price target of $33.98 implies an upside of 241.38% from current levels.

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company that develops high-fidelity vaccines. It develops broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. The company re-engineers the creation of highly complex vaccines through advanced chemistry and modern synthetic techniques.

While we acknowledge the potential of PCVX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PCVX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.